📰 Database Consortium News
Database Consortium News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Database Consortium. Real-time updates on events, politics, business and more.
June 6, 2024
Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.
June 3, 2024
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
June 2, 2024
ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
June 1, 2024
The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.
May 24, 2024
Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.
April 2, 2024
NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.
March 27, 2024
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (
March 27, 2024
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a biopharmaceutical company focused on developing
January 27, 2024
Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.
January 23, 2024
PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...